Results 131 to 140 of about 92,008 (245)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

open access: yesCancer Science, EarlyView.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa   +17 more
wiley   +1 more source

Laparoscopic Cholecystectomy for Ruptured Gallbladder Varices Diagnosed by Preoperative Endoscopic Ultrasonography: A Case Report. [PDF]

open access: yesSurg Case Rep
Hirano T   +8 more
europepmc   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye   +8 more
wiley   +1 more source

Associations of obesity, systemic inflammation, and hyperinsulinemia with the incidence of non‐communicable chronic disease and mortality: A prospective cohort study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity, systemic inflammation, and hyperinsulinemia are all features of metabolic syndrome and frequently occur together. We aimed to evaluate the association of body mass index (BMI) with incident non‐communicable chronic disease (NCD) or all‐cause mortality, independent of C‐reactive protein (CRP) and fasting insulin.
Natasha Wiebe   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy